TrialJournal of acquired immune deficiency syndromes (1999)2010

Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.

W David Hardy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.